The Wall Street Journal says to expect "an uptick in acquisitions of small and midsize drug companies" but that large pharma companies are "not going on reckless shopping sprees." Bristol-Myers' Karen LaRochelle said that many in Big Pharma do have a bit of cash "and there's a lot of pressure for us to build our pipelines." Merck's Richard Kender adds that, due to the current market, deals that in the past may have been deemed "marginal" are now more likely.